Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
Healthcare
$37.56 -0.55%
-$0.29 today
- Market cap
- $3.69B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
52W Low $30.00High $63.95
Volume 1.28M
Average 1.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$279.12M
FY 2025 · Annual
Investing Cash Flow
$218.00M
FY 2025 · Annual
+32.1% YoYFinancing Cash Flow
$117.11M
FY 2025 · Annual
+865.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| Deferred Income Tax | 58K | (44K) | (292K) | (8.86M) | (3.2M) |
| Stock-Based Compensation | 10.02M | 20.38M | 32.37M | 50.72M | 53.71M |
| Change in Working Capital | (2.65M) | (676K) | 5.64M | 5.71M | 4.36M |
| Accounts Receivables | (459K) | 1.76M | 130K | (614K) | 104K |
| Inventory | (2.97M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.97M | 8.06M | 3.93M | 8.53M | 5.51M |
| Other Working Capital | (2.19M) | (10.5M) | 1.57M | (2.2M) | (1.26M) |
| Other Non-Cash Items | 1.05M | 5.88M | (4.19M) | 2.82M | 9.38M |
| Operating Cash Flow | (69.5M) | (98.43M) | (145.33M) | (181.39M) | (279.12M) |
| Capital Expenditures | (2.05M) | (2.89M) | (5.62M) | (3.08M) | (799K) |
| Acquisitions (Net) | (144.75M) | 296M | 0 | 0 | 0 |
| Purchases of Investments | (389.47M) | (551.14M) | (793.91M) | (532.27M) | (355.66M) |
| Sales of Investments | 144.75M | 258.03M | 682.35M | 700.34M | 574.45M |
| Other Investing Activities | 144.75M | (296M) | 0 | 0 | 0 |
| Investing Cash Flow | (246.77M) | (296M) | (117.17M) | 165M | 218M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 447.28M | 277.77M | 353.49M | 12.08M | 117.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 260K | 705K | 35K | 47K | 0 |
| Financing Cash Flow | 447.54M | 278.47M | 353.52M | 12.13M | 117.11M |
| Effect of Forex Changes | (592K) | (2.48M) | 376K | (1.67M) | 458K |
| Net Change in Cash | 130.68M | (118.45M) | 91.4M | (5.93M) | 56.45M |
| Free Cash Flow | (71.55M) | (101.32M) | (150.94M) | (184.46M) | (279.92M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$345.9M
+ D&A$2.5M
+ Stock-Based Comp$53.7M
- Deferred Tax-$3.2M
+ Working Capital$4.4M
+ Other Non-Cash$9.4M
= Operating Cash Flow-$279.1M
- Capex-$799.0K
= Free Cash Flow-$279.9M
Analysis
FY2025 free cash flow is -$279.9M. FCF conversion is 80.9% of net income. Operating cash flow was -$279.1M, with capex of -$799.0K. The largest bridge item is Stock-Based Comp at $53.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| S-8 | S-8 filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 6, 2026 |
Does XENE generate free cash flow?
Xenon Pharmaceuticals Inc. (XENE) generated -$279.92M of free cash flow in fiscal 2025.
How much operating cash flow does XENE produce?
Operating cash flow was -$279.12M, before capital expenditures of $799,000.00.
Continue the stock analysis
Jump to another research area for this company.